News and Announcements
SUDA Amends Agreement with Amherst Pharmaceuticals
- Published December 11, 2015 11:49AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
10th December 2015, ASX Announcement
SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has amended its agreement with Amherst Pharmaceuticals in relation to ZolpiMist for insomnia and SUD-002 for nausea and vomiting.
Under the terms of the new agreement, SUDA has expanded it territorial rights to ZolpiMist to include South America, Central America and South America. As a result, SUDA now has a global license, excluding North America , to this US-registered oral spray of zolpidem tartrate for the treatment of insomnia. As per the cross-licencing agreement signed in January 2015, SUDA will pay Amherst a 6 to 12 per cent share of income from SUDA’s commercialisation of ZolpiMist. Business development discussions with prospective partners are progressing in several countries, including in the expanded territory.
To read the full announcement, please click here.